Erythromycin is a macrolide antibiotic with broad-spectrum antibacterial activity, particularly effective against Gram-positive bacteria (such as staphylococci and streptococci) and some atypical pathogens (such as mycoplasma, chlamydia, and Legionella). It is characterized by rapid oral absorption, but it is easily degraded by gastric acid. Therefore, it is often formulated as enteric-coated tablets or esters (such as erythromycin stearate) to improve stability. Clinically, it is mainly used to treat respiratory tract infections (such as pneumonia and bronchitis), skin and soft tissue infections, scarlet fever, Legionnaires' disease, and sexually transmitted diseases (such as non-gonococcal urethritis). In addition, erythromycin has certain gastrointestinal motility-promoting effects and can be used to enhance gastric emptying (such as in gastroparesis).

Natural Source: Erythromycin is the first natural macrolide antibiotic, directly extracted from the fermentation of Streptomyces erythreus, and is not fully chemically synthesized.

Acid-Alkali Sensitivity: Unstable in acidic conditions, it is easily degraded by gastric acid. Therefore, it is often formulated as enteric-coated tablets or esters (such as erythromycin stearate) to improve oral bioavailability.

Unique Antibacterial Spectrum: It has specific efficacy against atypical pathogens such as Mycoplasma and Legionella, serving as a first-line drug for treating "atypical pneumonia."

Hepatic Enzyme Inhibition: It significantly inhibits the CYP3A4 enzyme, prone to causing drug interactions (e.g., increasing blood concentrations of statins and cyclosporine).

Diverse Prodrug Derivatives: Semi-synthetic derivatives such as clarithromycin and azithromycin can be generated through structural modification, expanding clinical applications.

Dependence on Fermentation Process: Production is highly dependent on microbial fermentation technology, requiring strict monitoring of fermentation conditions and impurities for quality control.